MCK · News · 20260805N
Guidance / Outlook
MCKESSON CORP · 2026-08-05 · Importance 51 · Surprise 60
McKesson raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00, above its prior outlook and the $44.26 FactSet estimate. Management attributed the increase to strong oncology and specialty-drug performance, higher prescription volumes, and demand for specialty medicines. The company’s fiscal 2027 first-quarter revenue was $105.38 billion, up 7.7% year over year, although third-party reports noted potential moderation from pricing dynamics and margin pressure in specialty pharmaceuticals and GLP-1 drugs.